Charles Schwab Investment Management Inc. Grows Stake in BioMarin Pharmaceutical Inc. $BMRN

Charles Schwab Investment Management Inc. raised its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,556,117 shares of the biotechnology company’s stock after purchasing an additional 23,803 shares during the period. Charles Schwab Investment Management Inc. owned 0.81% of BioMarin Pharmaceutical worth $85,540,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Dodge & Cox increased its position in BioMarin Pharmaceutical by 1.4% during the 1st quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company’s stock valued at $1,057,186,000 after buying an additional 209,005 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of BioMarin Pharmaceutical by 1.3% during the second quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock worth $190,417,000 after acquiring an additional 43,185 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 127.9% during the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock valued at $203,987,000 after acquiring an additional 1,642,206 shares in the last quarter. Nuveen LLC purchased a new position in shares of BioMarin Pharmaceutical in the 1st quarter valued at approximately $184,475,000. Finally, Goldman Sachs Group Inc. raised its position in shares of BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after purchasing an additional 1,083,512 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $55.79 on Friday. The firm’s fifty day moving average is $53.80 and its two-hundred day moving average is $56.09. The firm has a market cap of $10.72 billion, a price-to-earnings ratio of 20.97, a PEG ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83. BioMarin Pharmaceutical Inc. has a one year low of $50.76 and a one year high of $73.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The company had revenue of $776.13 million for the quarter, compared to analysts’ expectations of $782.42 million. During the same quarter in the previous year, the business posted $0.91 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Wall Street Analyst Weigh In

BMRN has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price target on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Stifel Nicolaus reissued a “hold” rating and set a $61.00 price objective (down from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Tudor Pickering set a $88.00 price target on BioMarin Pharmaceutical in a research report on Monday, November 3rd. Finally, Wedbush reissued an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Sixteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.91.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.